Ubiquitination, an important type of protein posttranslational modification (PTM), plays a
crucial role in controlling substrate degradation and subsequently mediates the “quantity” …

Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the
development of cancer therapy. MDM2's activities extend from carcinogenesis to immunity to …

The transcription factor p53 is an important regulator of a multitude of cellular processes. In
the presence of genotoxic stress, p53 is activated to facilitate DNA repair, cell cycle arrest …

Inactivation of the transcription factor p53, through either direct mutation or aberrations in
one of its many regulatory pathways, is a hallmark of virtually every tumor. In recent years …

MDM2 and MDMX, negative regulators of the tumor suppressor p53, can work separately
and as a heteromeric complex to restrain p53's functions. MDM2 also has pro-oncogenic …

The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many
human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour …

Inactivation of the most important tumour suppressor gene TP53 occurs in most, if not all,
human cancers. Loss of functional wild-type p53 is achieved via two main mechanisms …

MDM2 and MDMX are the primary negative regulators of p53, which under normal
conditions maintain low intracellular levels of p53 by targeting it to the proteasome for rapid …

Abstract p53 is the major tumor suppressor and the most frequently inactivated gene in
cancer. p53 could be disabled either by mutations or by upstream negative regulators …

For more than 25 years, MDM2 and its homolog MDMX (also known as MDM4) have been
shown to exert oncogenic activity. These two proteins are best understood as negative …